Treatment heterogeneity in asthma: genetics of response to leukotriene modifiers.
about
Integrative systems biology approaches in asthma pharmacogenomicsConcentration-dependent noncysteinyl leukotriene type 1 receptor-mediated inhibitory activity of leukotriene receptor antagonists.Intermittent montelukast in children aged 10 months to 5 years with wheeze (WAIT trial): a multicentre, randomised, placebo-controlled trial.Genome-Wide Association Study Identifies Novel Pharmacogenomic Loci For Therapeutic Response to Montelukast in Asthma.The pharmacogenetics and pharmacogenomics of asthma therapyGenome-wide association study of leukotriene modifier response in asthma.Nutrigenetic response to omega-3 fatty acids in obese asthmatics (NOOA): rationale and methodsNew approaches to managing asthma: a US perspectiveAbsorption of montelukast is transporter mediated: a common variant of OATP2B1 is associated with reduced plasma concentrations and poor response.Phenotypic predictors of long-term response to inhaled corticosteroid and leukotriene modifier therapies in pediatric asthmaThe pharmacogenetics of asthma treatment.Leukotriene pathway in sickle cell disease: a potential target for directed therapy.Impact of montelukast on asthma associated with rhinitis, and other triggers and co-morbidities.Montelukast, current indications and prospective future applications.Genetic and Epigenetic Components of Aspirin-Exacerbated Respiratory Disease.Clinically relevant pharmacogenomic testing in pediatric practice.Montelukast Disposition: No Indication of Transporter-Mediated Uptake in OATP2B1 and OATP1B1 Expressing HEK293 Cells.Developing the evidence base for applying pharmacogenomics: proceeds from DIA Workshop IV--Breakout Session 1.Effect of citrus juice and SLCO2B1 genotype on the pharmacokinetics of montelukast.Pharmacogenetics of asthma controller treatment.The phosphatidylinositide 3-kinase (PI3K) signaling pathway is a determinant of zileuton response in adults with asthma.
P2860
Q26861541-BEC483EA-2318-4550-A07F-ACC9C9F14D0AQ33677296-90CD1008-87DF-43C0-B2CB-58BD567D63DFQ34303847-459B3CE2-BC04-4E11-AAD6-DD3245536148Q35665779-EA84B490-EF09-4E73-857D-9B8285E81B41Q35819993-39EDADA3-B29C-4E0D-BEF7-960B185E6941Q36342927-184395B9-0E20-41D6-869A-B1AF9D938AF1Q36800748-6DDD2387-AB96-43E6-9CB3-F05B13A78980Q36823534-F9C73CE3-EBE4-440F-89E2-11FAED10469FQ37094329-86551609-0CE3-496D-B6A0-FCDE88207279Q37142937-8A812D08-968F-440D-8293-4CE8202A5889Q37343578-D12EC24E-062C-470E-91A8-2B1ADAD99B09Q37810108-8D4E7F66-4EEE-4224-9F46-BDF521F65BFFQ38120057-B973F7AC-5E15-4398-861E-6C404B01CFEAQ38835130-EAEC9EB6-A1B0-4ADF-B596-18912F825CB7Q38973971-6F7375D2-E4BA-4EF0-9279-A7F29B782475Q39197183-E174730F-B862-4D44-BD43-AEA738077283Q40180951-FAECC126-02BA-4536-BDFB-7C85BDA75DE0Q42607208-A72E4639-327B-41AD-AFF9-A967E0D86637Q44077554-4B90D385-07EE-40C5-9697-4A4C91C6A93CQ46107352-C7508B20-E772-4407-A03F-8B2433CF86D5Q47212616-132BE49D-6679-4750-9BFB-341FAA02A306
P2860
Treatment heterogeneity in asthma: genetics of response to leukotriene modifiers.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Treatment heterogeneity in asthma: genetics of response to leukotriene modifiers.
@ast
Treatment heterogeneity in asthma: genetics of response to leukotriene modifiers.
@en
type
label
Treatment heterogeneity in asthma: genetics of response to leukotriene modifiers.
@ast
Treatment heterogeneity in asthma: genetics of response to leukotriene modifiers.
@en
prefLabel
Treatment heterogeneity in asthma: genetics of response to leukotriene modifiers.
@ast
Treatment heterogeneity in asthma: genetics of response to leukotriene modifiers.
@en
P2860
P356
P1476
Treatment heterogeneity in asthma: genetics of response to leukotriene modifiers.
@en
P2093
John J Lima
P2860
P2888
P304
P356
10.1007/BF03256228
P577
2007-01-01T00:00:00Z